ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

vonoprazan

Also written as “TAK-438”, “Vonoprazan” and “Vonoprazan (Reference)”.

Its studies are mostly in Esophagitis · Stomach Ulcer · Gastroesophageal Reflux · Heartburn · Duodenal Ulcer, led by 5 companies.

Drug pageVonoprazan: every studyMany companies study it; this page follows only the 48 they lead. All 100 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Feb 8, 201648 company-led studies, 2 open or runningNext primary completion: Oct 20, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takedaits history only310 open or runningphase 4since Feb 8, 2016Sep 16, 2011none ahead
Phathom Pharmaceuticals142 open or runningphase 3since Oct 10, 2019Oct 10, 2019Oct 20, 2027phase 3 · NCT07752407
Genuine Research Center, Egyptits history only10 open or runningphase 1since Nov 14, 2021Nov 14, 2021none ahead
Hanlim Pharm.its history only10 open or runningphase 1since Oct 14, 2024Oct 14, 2024none ahead
Humanis Saglık Anonim Sirketiits history only10 open or runningphase 1since Dec 9, 2025Dec 9, 2025none ahead

Also a collaborator on its studies: Richmond Pharmacology.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Phathom Pharmaceuticals only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 10, 2019First study: phase 3 study in Erosive EsophagitisFirst studyNCT04124926 · 1,027 enrolled · United States, Bulgaria, Czechia and more
  2. Nov 15, 2019Phase 3 study in Helicobacter Pylori InfectionNCT04167670 · 1,046 enrolled · United States, Bulgaria, Czechia and more
  3. Sep 4, 20202 phase 1 studiesNCT04545944, NCT04558216
  4. Jan 19, 2021Phase 1 study in Healthy ParticipantsNCT04729101 · 44 enrolled · United States
  5. Mar 11, 2021Phase 2 study in HeartburnNCT04799158 · 458 enrolled · United States
  6. Jan 4, 2022Phase 3 study in HeartburnNCT05195528 · 776 enrolled · United States
  7. Apr 18, 2022Phase 1 study in Gastroesophageal RefluxNCT05343364 · 24 enrolled · United States
  8. May 4, 2022Phase 1 study in Gastroesophageal RefluxNCT05366738 · 27 enrolled · United States
  9. Oct 24, 2023Phase 1 study in Gastroesophageal RefluxNCT06106022 · 22 enrolled · United States
  10. Apr 25, 2024Phase 1 study in HeartburnNCT06391177 · 15 enrolled · United States
  11. Feb 14, 2025Phase 1 study in Healthy VolunteersNCT06831344 · 25 enrolled · United States
  12. Feb 24, 2025Phase 2 study in Eosinophilic EsophagitisNCT06851559 · 95 enrolled · United States
  13. Aug 3, 2026Phase 3 study in Gastroesophageal RefluxNCT07752407 · 500 planned · United States

Ahead

  1. Oct 20, 2027Primary completion: phase 3 study in Gastroesophageal RefluxNCT07752407

TargetBeta

ATP4A →ATP4B →read by rule
“Potassium-transporting ATPase inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
EsomeprazoleruleAstraZenecaphase 4129
RabeprazoleruleEisaiphase 466
OmeprazoleruleAstraZenecaphase 456
tegoprazanruleHK inno.Nphase 448
fexuprazanruleDaewoong Pharmaceuticalphase 429

Studies

All 14 Phathom Pharmaceuticals leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07752407Gastroesophageal Reflux · United States3RecruitingOct 20, 2027500
NCT06851559Eosinophilic Esophagitis · United States2Active, not recruitingSep 11, 202695
NCT06831344Healthy Volunteers · United States1CompletedApr 5, 202525
NCT06391177Heartburn · United States1CompletedSep 13, 202415
NCT06106022Gastroesophageal Reflux · United States1CompletedApr 16, 202422
NCT05366738Gastroesophageal Reflux · United States1CompletedJul 1, 202227
NCT05343364Gastroesophageal Reflux · United States1CompletedMay 30, 202324
NCT05195528Heartburn · United States3CompletedNov 21, 2022776
NCT04799158Heartburn · United States2CompletedDec 16, 2021458
NCT04729101Healthy Participants · United States1CompletedJun 12, 202144
NCT04558216Healthy Participants · United States1WithdrawnFeb 7, 20210
NCT04545944Healthy Volunteers · United States1CompletedNov 13, 202020
NCT04167670Helicobacter Pylori Infection · United States, Bulgaria, Czechia and more3CompletedMar 10, 20211,046
NCT04124926Erosive Esophagitis · United States, Bulgaria, Czechia and more3CompletedJul 29, 20211,027

How it is read

Names in the registry

  • “TAK-438”, 32 entries
  • “Vonoprazan”, 20 entries
  • “Vonoprazan (Reference)”, 1 entry
  • “Vonoprazan Tablets”, 1 entry
  • “VOQUEZNA® Tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.